Saniona AB (FRA:30S) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:30S Saniona AB FRA:30S
59 GF Score
Price €1.17
GF Value €2.41
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Saniona AB FFO per Share?

FFO per Share only applies to REITs.

FRA:30S
59GF Score
Saniona AB FRA:30S
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Saniona AB (FRA:30S) Overvalued in 2026?

Based on GuruFocus' analysis, Saniona AB stock appears to be undervalued. The current stock price of €1.17 is trading 51.4% below its estimated GF Value™ of €2.41. GuruFocus considers Saniona AB to be Significantly Undervalued.

Key valuation signals for FRA:30S:

  • FFO per Share:
  • GF Value™: €2.41 vs. price of €1.17 (51.4% below fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the FRA:30S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Saniona AB Business Description

Address Murervangen 42, Glostrup, DNK, DK-2600
Saniona AB researches and develops drugs for the treatment of diseases of the central nervous system, autoimmune diseases, metabolic diseases, and the treatment of pain. It develops a technology platform that enables the investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors, and potassium channels. The company product pipeline includes Tesomet, SAN711, Tesofensine, SAN903, and SAN2219. Geographically, it operates in USA, Sweden, Germany, Denmark, and United Kingdom, out of which it derives maximum revenue from USA.
59GF Score

Get the complete analysis for FRA:30S

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.17
Price
€2.41
GF Value